The assignment gets bigger
Obesity, heart and kidney research · 2018–2025
How did one assignment turn into several?
Subject One returns to the room marked BLOOD SUGAR. Someone has added doors for weight, heart and kidneys. “Did I apply for all of these?” Doctide hands him three separate folders. “No shortcuts. Each door needs its own evidence.”
What changes here
Obesity was deliberately studied, not discovered by accident after approval. Later heart and kidney questions needed their own trials. [1] [4] [5]
Read the study details & dates
Obesity was a deliberate research question
An obesity-specific Phase 2 trial enrolled 957 people in 2015–2016. Weight management was being investigated before Ozempic’s approval; it was not simply a surprise discovered afterward. [1]
STEP-1 and Wegovy
STEP-1 enrolled 1,961 adults with obesity or overweight without diabetes. Over 68 weeks, mean weight change was −14.9% versus −2.4% with placebo, alongside lifestyle intervention. Gastrointestinal effects and treatment discontinuations also occurred. Wegovy’s initial US weight-management approval followed on June 4, 2021. [2] [3]
What happened after stopping?
In the STEP-1 extension, participants regained about two-thirds of their prior weight loss over the year after semaglutide and the structured lifestyle intervention were withdrawn. This follow-up shows why an on-treatment result is not a promise of permanent weight loss. [7]
A cardiovascular indication
FDA approved Wegovy to reduce major cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. SELECT recorded events in 6.5% versus 8.0% with placebo. This is a defined population, not a universal heart-protection claim. [4]
The kidney question
FLOW studied 3,533 people with type 2 diabetes and chronic kidney disease. The primary kidney/CV-death composite was reduced by 24% relative over a median 3.4 years. Ozempic’s kidney-related indication followed for that population. [5] [6]
What this does not establish
Different populations and endpoints require different trials. A cardiovascular result, a kidney composite and a weight change are not interchangeable measures of success.
Original sources
- Obesity Phase 2 primary publication
- STEP-1 primary publication
- FDA Wegovy regulatory background
- FDA cardiovascular approval announcement (2024)
- FLOW primary publication (2024)
- Novo Nordisk kidney-indication announcement (2025; sponsor release)
- STEP-1 withdrawal extension (2022)
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story